Welcome To The Resverlogix HUB On AGORACOM

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Trial and a Phase 2 Kidney Trial is Planned for 2017**

Free
AGORACOM NEWS FLASH

AGORACOM Welcomes Back Grizzly Discoveries (GZD: TSX-V)

World class gold and base metal deposits in British Columbia; and diamonds in Alberta $GZD.ca

  • More than 9 million oz Au produced or as resources in a radius of less than 70KM to Greenwood project
  • Holds, or has an interest in, metallic and industrial mineral permits for potash totaling more than 364,000 acres along the Alberta-Saskatchewan border
  • Drillholes with up to 31.1% K2O from assays on recent drill program
  • Portions of Greenwood Project being explored by Kinross through option agreement

Gzdnew

Hub On AGORACOM / Learn More!

-----------------------------------------------------

BREAKING NEWS OUT OF 2 AGORACOM CLIENTS

Namaste Announces Signing of MOU With Marijuana.Ca

  • Entered MOU with Marijuana.Ca, operator of www.marijuana.ca
  • Signing of MOU represents further achievement of the Company’s objective to increase site traffic and develop customer data in the Canadian market
  • Also coincides with the upcoming launch of www.everyonedoesit.ca, which the Company will use to further expand its position in the Canadian market

 

Nlogo

Hub On AGORACOM / Read Release

---------------------------------------------------------

Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of dried Cannabis

  • Announces launch of its Double-Blind Phase I Study
  • Purpose to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis by Smoking/Inhalation in Healthy Male and Female Volunteers
  • Trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination

Tbp large

Hub On AGORACOM / Read Release

Message: Q1 events list updated

One of the Q1 events is a Keystone Symposia (see event details below). Keystone Symposia are GREAT scientific meetings. Norm Wong presents on February 2nd discussing BET inhibitors in cardiovascular disease AND rheumatoid arthritis. It's been a while since we've heard from either Resverlogix or Zenith on their arthritis program. Hopefully that is a sign that the arthritis program is still alive and well.

 

Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics

January 29—February 2, 2017

Sheraton Seattle Hotel, Seattle, Washington, USA

 

Thursday February 2

Norm Wong, Resverlogix Corporation, Canada 

Short Talk: Selective BET Inhibitors are Useful for Normalizing Inflammation Leading to Reduced Cardiovascular Disease (CVD) in Humans and in an Animal Model of Rheumatoid Arthritis

 

Share
New Message
Please login to post a reply